

HLA-A\*11:01&B2M&KRAS G12V (VVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-

## General Information

**Synonyms:** KI-RAS;MHC;K-RAS2A;RALD;NS3;K-RAS2B;KRAS2;K-RAS4A;GTPase Kras;CFC2;KRAS;KRAS1;K-RAS4B;K-Ras 2;C-K-RAS;NS;RASK2

**Protein Construction:** Gly25-Thr305 (HLA-A\*11:01), Ile21-Met119 (B2M) and VVGAVGVGK peptide

**Species:** Human

**Expression Host:** E. coli

**Accession:** AAV53343.1(HLA-A\*11:01)&P61769(B2M)&VVGAVGVGK

## QC Testing

**Biological Activity:** Activity has not been tested. It is theoretically active, but we cannot guarantee it.

**Formulation:** Supplied as 0.22 µm filtered solution in 20 mM Tris, 200 mM NaCl, 0.2% BSA (pH 8.0).

## Preparation and Storage

### Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

### Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

## Protein Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

**This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use**

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481